Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jun 10;74(11):1979-1985.
doi: 10.1093/cid/ciab750.

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)

Jane R Schwebke  1 , Ryan Sobel  2 , Janet K Gersten  3 , Steven A Sussman  4 , Samuel N Lederman  5 , Mark A Jacobs  6 , B Todd Chappell  7 , David L Weinstein  8 , Alfred H Moffett  9 , Nkechi E Azie  10 , David A Angulo  10 , Itzel A Harriott  10 , Katyna Borroto-Esoda  11 , Mahmoud A Ghannoum  12 , Paul Nyirjesy  2 , Jack D Sobel  13
Affiliations
Clinical Trial

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)

Jane R Schwebke et al. Clin Infect Dis. .

Abstract

Background: Current treatment of vulvovaginal candidiasis (VVC) is largely limited to azole therapy. Ibrexafungerp is a first-in-class triterpenoid antifungal with broad-spectrum anti-Candida fungicidal activity. The objective of this study was to evaluate the efficacy and safety of ibrexafungerp compared with placebo in patients with acute VVC.

Methods: Patients were randomly assigned 2:1 to receive ibrexafungerp (300 mg twice for 1 day) or placebo. The primary endpoint was the percentage of patients with a clinical cure (complete resolution of vulvovaginal signs and symptoms [VSS] = 0) at test-of-cure (day 11 ± 3). Secondary endpoints included the percentage of patients with mycological eradication, overall success (clinical cure and mycological eradication), clinical improvement (VSS ≤ 1) at test-of-cure, and symptom resolution at follow-up (day 25 ± 4).

Results: Patients receiving ibrexafungerp had significantly higher rates of clinical cure (50.5% [95/188] vs 28.6% [28/98]; P = .001), mycological eradication (49.5% [93/188] vs 19.4% [19/98]; P < .001), and overall success (36.0% [64/178] vs 12.6% [12/95]; P < .001) compared with placebo. Symptom resolution was sustained and further increased with ibrexafungerp compared with placebo (59.6% [112/188] vs 44.9% [44/98]; P = .009) at follow-up. Post hoc analysis showed similar rates of clinical cure and clinical improvement at test-of-cure for Black patients (54.8% [40/73] and 63.4% [47/73], respectively) and patients with a body mass index >35 (54.5% [24/44] and 68.2% [30/44], respectively) compared with overall rates. Ibrexafungerp was well tolerated. Adverse events were primarily gastrointestinal and mild in severity.

Conclusions: Ibrexafungerp provides a promising safe and efficacious oral treatment that mechanistically differs from current azole treatment options for acute VVC.

Keywords: Candida albicans; SCY-078; ibrexafungerp; placebo; vulvovaginal candidiasis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient disposition. Abbreviations: FU, follow-up; ITT, intention-to-treat; mITT, modified intention-to-treat; TOC, test of cure.
Figure 2.
Figure 2.
Select efficacy endpoints. A, Efficacy outcomes at TOC visit (day 10): clinical cure (ibrexafungerp, 95/188 patients; placebo, 28/98 patients), mycological eradication (ibrexafungerp, 93/188 patients; placebo, 19/98 patients), and overall success (ibrexafungerp, 64/178 patients; placebo, 12/95 patients). B, Efficacy outcomes at TOC visit (day 10) for patients with C. albicans infections, clinical cure (ibrexafungerp, 88/173 patients; placebo, 25/90 patients), mycological eradication (ibrexafungerp, 89/173 patients; placebo, 17/90 patients), and overall success (ibrexafungerp, 61/163 patients; placebo, 11/88 patients). *P = .001, **P < .001 for comparisons between ibrexafungerp and placebo. Abbreviation: TOC, test of cure.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Makanjuola O, Bongomin F, Fayemiwo SA. An update on the doles of non-albicans Candida species in vulvovaginitis. J Fungi 2018; 4:121. - PMC - PubMed
    1. Martin Lopez JE. Candidiasis (vulvovaginal). BMJ Clin Evid 2015; 2015:0815. - PMC - PubMed
    1. Mendling W, Brasch J, Cornely OA, et al. . Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses 2015; 58:1–15. - PubMed
    1. Jeanmonod R, Jeanmonod D. Vaginal candidiasis. Available at: https://www.ncbi.nlm.nih.gov/books/. Accessed 9 March 2021.
    1. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2016; 214:15–21. - PubMed

Publication types